Go to the profile of Amal Therapeutics

Amal Therapeutics

 
  • Switzerland

About Amal Therapeutics

AMAL Therapeutics SA is a spin-off from the University of Geneva active in cancer immunotherapy. AMAL has developed a unique protein-based immunization platform called KISIMA® providing activation signal to dendritic cells simultaneously to priming both helper and killer cells for various antigens and HLA restrictions. This first-in-class platform is offering the opportunity to develop standardized and indicationtailored active immunotherapies. The company’s lead product ATP128 is currently being developed for metastatic and advanced colorectal cancer.

Therapeutic Areas

Oncology

Technologies

Vaccines

Company Type

Biotechnology – Therapeutics

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

September 2018